NASHVILLE, Tenn. / Nov 20, 2023 / Business Wire / Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences:
BTIG 3rd Annual Ophthalmology Day
Format: Fireside Chat (Virtual)
Date/Time: Monday, November 27, 2023, at 1:30 p.m. ET
Piper Sandler 35th Annual Healthcare Conference (The Lotte New York Palace, New York, NY)
Format: Fireside Chat (In-Person)
Date/Time: Thursday, November 30, 2023, at 8:00 a.m. ET
Harrow management will be available for one-on-one meetings during both conferences. Investors interested in meeting with management should contact their BTIG or Piper Sandler representative to request a meeting.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. For more information about Harrow, please visit harrow.com.
Last Trade: | US$37.45 |
Daily Change: | -0.27 -0.72 |
Daily Volume: | 291,213 |
Market Cap: | US$1.390B |
August 11, 2025 May 14, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load